{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-045324","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.334749+00:00","generated_at":"2026-05-22T07:36:08.419301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cognition Therapeutics Q1 net loss $8.5M; cash $16.4M; requests EOP2 for Alzheimer's","bullets":["Net loss of $8.5M ($0.14 per share) compared to $9.2M ($0.27) in Q1 2024.","Cash and equivalents $16.4M plus $47M in NIH grants; runway into Q4 2025.","Requested End-of-Phase 2 meeting with FDA to discuss Alzheimer's SHINE study and registrational trial.","Phase 2 SHIMMER study in dementia with Lewy bodies accepted for oral presentation at AAIC July 2025.","Presenting two posters at ARVO on zervimesine's role in regulating lipid metabolism and retinal cell protection."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-045324","json":"https://secwatch.observer/filing/0001104659-25-045324.json","markdown":"https://secwatch.observer/filing/0001104659-25-045324.md","text":"https://secwatch.observer/filing/0001104659-25-045324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925045324/0001104659-25-045324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925045324/tm2514197d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:36:08.419301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}